Goodwin

Everlaw Named #1 Ediscovery Platform Globally in G2 Fall 2023 Grid Report

Retrieved on: 
Wednesday, September 20, 2023
High performance organization, Goodwin, Practice of law, Online shopping, G2

OAKLAND, Calif., Sept. 20, 2023 /PRNewswire/ -- Everlaw, the cloud-native investigation and litigation platform, today announced that it has been named number one of 116 vendors in the G2 Fall 2023 Ediscovery Grid Report. With an overall rating of 4.7 out of 5, this marks Everlaw's second #1 ranking in G2 this year further validating its innovation, customer satisfaction and leadership trajectory for ediscovery in the legal industry. Read the report here.

Key Points: 
  • OAKLAND, Calif., Sept. 20, 2023 /PRNewswire/ -- Everlaw , the cloud-native investigation and litigation platform, today announced that it has been named number one of 116 vendors in the G2 Fall 2023 Ediscovery Grid Report.
  • The High Performer designations in Ediscovery Software and Public Records Management are driven primarily by the top rankings that Everlaw has earned by verified customers for customer satisfaction.
  • Highlights from verified customer feedback on the G2 platform include:
    "I like that Everlaw is flexible and, by far, the easiest platform to use out of all ediscovery applications."
  • – Lori W.
    The G2 ranking evaluates ediscovery software that enables the review of electronic documents and information for use during litigation.

Analysis Group Supports Testimony in Pay-for-Delay HIV Treatment Antitrust Matter

Retrieved on: 
Tuesday, August 8, 2023
Efavirenz/emtricitabine/tenofovir, Teva Pharmaceuticals, Teva, HIV, Health, Proskauer Rose, Element, Kirkland & Ellis, Harvard Medical School, Analysis Group, Gilead Sciences, United States district court, District court, Joseph, State, Hospital, Policy, Massachusetts General Hospital, Goodwin, Goodwin Procter, Pharmaceutical industry

BOSTON, Aug. 8, 2023 /PRNewswire/ -- Analysis Group , one of the largest international economics consulting firms, supported academic and medical affiliate Anupam B. Jena in preparing testimony assessing damages and evaluating elements of innovation in developing Gilead Science's HIV treatments.

Key Points: 
  • BOSTON, Aug. 8, 2023 /PRNewswire/ -- Analysis Group , one of the largest international economics consulting firms, supported academic and medical affiliate Anupam B. Jena in preparing testimony assessing damages and evaluating elements of innovation in developing Gilead Science's HIV treatments.
  • Gilead, a Kirkland & Ellis and Proskauer Rose client, was a co-defendant with Teva Pharmaceuticals, a Goodwin Procter client, in a rare pay-for-delay antitrust jury trial.
  • In the matter In re: HIV Antitrust Litigation, health plans and insurers claimed they were overcharged for the Gilead-brand HIV drugs Truvada and Atripla, as well as for the generic versions manufactured by Teva once they became available.
  • An Analysis Group team led by Managing Principal Pavel Darling , Principal Richard Mortimer , and Manager Ngoc Pham assisted Dr. Jena in the preparation of his testimony.

Guild Names Dan Haley as New General Counsel

Retrieved on: 
Friday, April 7, 2023
Professional Services, Education, Legal, Human Resources, Continuing, Training, Workforce, General counsel, Emery, McDermott Will & Emery, Harvard Law School, Civil Service (United Kingdom), Middlebury College, Corporation, Corporate lawyer, Knowledge, Goodwin, Goodwin Procter, Management, Guild

Guild , the leader in opportunity creation for America’s workforce, today announced that Dan Haley will join the company as its new General Counsel and Corporate Secretary.

Key Points: 
  • Guild , the leader in opportunity creation for America’s workforce, today announced that Dan Haley will join the company as its new General Counsel and Corporate Secretary.
  • In this role, Haley will lead the company’s legal teams, overseeing all related functions, and report to Guild’s CEO, Rachel Romer.
  • Haley joins Guild from Sprinklr where he served as the company’s General Counsel and Corporate Secretary for three and a half years.
  • We’re thrilled to bring on a leader who’s committed to excellence and creating opportunity.”
    “I was immediately drawn to Guild for its mission—to unlock opportunity for America’s workforce—and its business model that enables it to truly deliver on that mission,” said Dan Haley, Guild’s General Counsel.

Goodwin Elects Anthony McCusker as Firm Chair

Retrieved on: 
Wednesday, April 5, 2023
Consulting, Professional Services, Legal, Silicon, Partnership, Allocation, Goodwin, Partner (business rank), Multimedia, Culture, Lawyer, Chair, McCusker

Global law firm Goodwin announced today the election of Anthony McCusker as the firm’s next Chair.

Key Points: 
  • Global law firm Goodwin announced today the election of Anthony McCusker as the firm’s next Chair.
  • McCusker will succeed Robert Insolia , who has served as Chair since 2019 and as Managing Partner from 2012 to 2019.
  • As Chair, McCusker will drive both strategic initiatives and culture, working closely with Managing Partner Mark Bettencourt .
  • “Thanks to the trust our clients put in us and to the commitment of our lawyers and business professionals, Goodwin has been and continues to be on an extraordinary trajectory,” said McCusker.

HarborOne Bancorp, Inc. Announces 2023 Annual Meeting Information

Retrieved on: 
Friday, February 3, 2023
Finance, Banking, Accounting, Professional Services, Legal, Annual Meetings of the International Monetary Fund and the World Bank Group, Annual general meeting, Goodwin, Bottled water, Phoenix metropolitan area arterial roads

HarborOne Bancorp, Inc. (the “Company”) (NASDAQ: HONE), announced today that the Company’s 2023 annual meeting of shareholders (the “Annual Meeting”) will be held on May 17, 2023 at 10:00 a.m. local time, at Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts.

Key Points: 
  • HarborOne Bancorp, Inc. (the “Company”) (NASDAQ: HONE), announced today that the Company’s 2023 annual meeting of shareholders (the “Annual Meeting”) will be held on May 17, 2023 at 10:00 a.m. local time, at Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts.
  • Stockholders of record of the Company’s common stock as of the close of business on March 21, 2023 are entitled to vote at the Annual Meeting.
  • Additional information regarding the Annual Meeting will be provided in the Company’s proxy statement.

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 4, 2023
JPM, Precision medicine, EST, SALT, Myriad Genetics, Genetic testing, Goodwin, MYGN, Genetics, Conference, Association for Molecular Pathology v. Myriad Genetics, Inc., Pharmaceutical industry

SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST.

Key Points: 
  • SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST.
  • The presentation will be available through a live webcast on the Myriad Genetics Investor Relations website .
  • An archived edition of the presentation will be available later that day.
  • Also during the JPM Conference, Nicole Lambert, chief operating officer, will be participating in a panel discussion about global precision medicine at the Goodwin + KPMG 4th Annual Symposium on Wednesday, Jan. 11 at 10:45 a.m. PST/1:45 p.m. EST.

Xailient brings Privacy-Safe Face Recognition to the Smart Home with Abode Systems

Retrieved on: 
Wednesday, December 28, 2022
Carney, DIY, SAN, Architecture, Dwelling, Strategic partnership, AI, Privacy, Mitigation, Future of Privacy Forum, Collection, Data collection, Facial recognition system, Goodwin, Facial recognition, Future, Nice, ADT, Fellow, Medical device, Video game console, Cryptocurrency, Online shopping

SAN FRANCISCO, Dec. 28, 2022 /PRNewswire/ -- Orchestrait is the world's first privacy-safe face recognition solution that uses state-of-the-art artificial intelligence (AI) at the edge to ensure full compliance with biometric data and privacy laws across the world.

Key Points: 
  • Xailient has partnered with leading smart home security provider Abode Systems to bring the first Orchestrait integration to market.
  • The new Abode Wireless Video Doorbells will feature face recognition at the edge, providing precise and accurate face recognition with privacy-safe technology.
  • Xailient has partnered with Abode, a leading smart home security company, to bring privacy-safe Face Recognition into Abode's new video doorbells.
  • According to Abode Systems CEO Chris Carney, "Partnering with Xailient has allowed us to deliver advanced facial recognition while still protecting our customers' privacy.

The New Classroom Instruction That Works: The Best Research-Based Strategies for Increasing Student Achievement has arrived!

Retrieved on: 
Wednesday, November 30, 2022
Marketing, Science, Learning, Cognitive science, Student, Education, Does, School, Research, Collection, Goodwin, Educational leadership, Tutoring, Medicine, ASCD

ASCD, the nation's leading association for K12 educator professional development, announced the publication of The New Classroom Instruction That Works: The Best Research-Based Strategies for Increasing Student Achievement , copublished with McREL International.

Key Points: 
  • ASCD, the nation's leading association for K12 educator professional development, announced the publication of The New Classroom Instruction That Works: The Best Research-Based Strategies for Increasing Student Achievement , copublished with McREL International.
  • The result is a streamlined set of teaching strategies that are practical, straightforward, focused on what works, and powered by updated research that represents todays highly diverse classrooms.
  • Our professional learning services let educators chart their own learning journey, as educators, and as leaders, so they and their students can flourish.
  • Learn more at www.ascd.org and visit ASCD's virtual learning community to view a full slate of educator professional learning opportunities and conferences.

Mosie Baby Announces its New Medical Advisory Board

Retrieved on: 
Thursday, November 17, 2022
Family, Male, Endocrinology, Reproductive medicine, Health, Infertility, Gynaecology, MD, ACOG, Government, SXSW, Commerce, Newport News Department of Parks, Recreation and Tourism, University of California, Irvine Medical Center, University, American College of Obstetricians and Gynecologists, Columbia Law School, FDA, IVI, Privacy, Pregnancy, Insemination, Private sector, Urology, Goodwin, Book, Patient, The Lady's Complete Guide, American College, MOSIS, Education, Fertility, Vasectomy, Penis, Pharmaceutical industry, Medicine, Management, Birth control, Milk, Author

AUSTIN, Texas, Nov. 17, 2022 /PRNewswire/ -- Mosie Baby, a leader in reproductive healthcare and creator of the patented Mosie Syringe, today is unveiling its medical advisory board which includes Dr. Sandra Carson, MD FACOG, Delphine O'Rourke, Partner at Goodwin and Adjunct Professor, Columbia Law School, Kwame Ulmer, MedTech Impact Partners' Managing Partner, and Dr. Aaron Spitz, Urologist and Author of 'The Penis Book: A Doctor's Complete Guide to the Penis - From Size to Function and Everything in Between.' Launched in 2016 with The Mosie Kit, a groundbreaking at-home insemination kit featuring the patented Mosie syringe, Mosie Baby is on a mission to empower people with the tools needed to grow their families on their own terms. Mosie's medical board of advisors will seek to continue this mission as the brand expands its footprint, gears up for new product innovation and continues to democratize access to family building over the coming year.

Key Points: 
  • Launched in 2016 with The Mosie Kit, a groundbreaking at-home insemination kit featuring the patented Mosie syringe, Mosie Baby is on a mission to empower people with the tools needed to grow their families on their own terms.
  • "We are thrilled to officially bring on board this esteemed group of clinical, regulatory, and legal experts who can help support Mosie Baby as we help and support more people building their families from the privacy of their own homes," said Maureen Brown, Co-Founder of Mosie Baby.
  • Mosie Baby is the developer and inventor of The Mosie Kit, a groundbreaking at-home insemination kit featuring the patented Mosie syringe.
  • To learn more about Mosie Baby, please visit mosiebaby.com or follow them on Instagram , Facebook , Twitter , and on TikTok @mosiebaby.

Senda Biosciences Bolsters Executive Leadership Team

Retrieved on: 
Wednesday, October 19, 2022
Reed Smith, LinkedIn, RNA transfection, Therapy, Tech, Pfizer, Vaccine, Cornell Law School, Degenerative disease, Takeda Oncology, Assessment, General counsel, Vanderbilt University School of Medicine, Capital market, Patient, Twitter, Tissue, Program, Cell, Cooley, AMAG Pharmaceuticals, Multimedia, Flagship Pioneering, SVP, Lawyer, Cooley LLP, University, Rest, Vertex Pharmaceuticals, Kidney disease, Industry, Department of Biochemistry, University of Oxford, Lori, Department, Cell biology, Goodwin, Intellectual property, Carroll University, LLP, Management, Pharmaceutical industry, Biology

"We're delighted to add Lori and Barbara to the Senda leadership team as we work to build a world-class organization," said Guillaume Pfefer, Ph.D., Chief Executive Officer of Senda Biosciences and Partner at Flagship Pioneering.

Key Points: 
  • "We're delighted to add Lori and Barbara to the Senda leadership team as we work to build a world-class organization," said Guillaume Pfefer, Ph.D., Chief Executive Officer of Senda Biosciences and Partner at Flagship Pioneering.
  • In her role at Senda, she will ensure efficient operations in our R&D and platform functions and help develop our clinical trials and regulatory capabilities.
  • Barbara joined Cooley as part of a 13-person Capital Markets team from Reed Smith LLP, where she commenced her career.
  • Senda Biosciences, Inc. is committed to bringing life-changing treatments to patients by harnessing nature's code to program human cellsboth from within and from outsidefor targeted, potent, and tunable medicines.